Rheumatoid Arthritis Treatment Help Slow or Stop the Disease Symptoms And Prevent Further Damage to the Joints

 

Rheumatoid Arthritis Treatment

Rheumatoid Arthritis is an autoimmune disease, which means that the immune system of an individual mistakenly attacks body’s own cells and tissues. The symptoms of RA may vary from mild to severe, and they can impact the quality of patient’s life. Rheumatoid arthritis treatment can slow or stop the symptoms and prevent further damage to the joints and other organs.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used as Rheumatoid Arthritis Treatment. They decrease inflammation and can ease pain, however they do not cure the condition. NSAIDs come in over-the-counter and prescription varieties, including ibuprofen (Advil, Motrin) and naproxen sodium (Aleve). They are safe to use and usually have few side effects.

Intra-articular corticosteroids, or steroids injected into the joint, can also be effective for controlling flare-ups of RA. They can be used for several months or a few weeks at a time, depending on the severity of the symptoms.

DMARDs, or disease-modifying antirheumatic drugs, can help slow the progression of rheumatoid arthritis by lowering the body’s immune response to the damage it causes to the joints. These include methotrexate (Trexall, Otrexup), leflunomide (Arava), hydroxychloroquine (Plaquenil), and sulfasalazine (Azulfidine).

They are often given in combination with other DMARDs to maximize their effect on patient’s Rheumatoid Arthritis. The doctor will start patient on a lower dose and increase it over a few months as their symptoms improve.

Rheumatoid Arthritis Treatment drugs reduce the production of inflammatory chemicals called cytokines. Cytokines have an important role in RA by increasing the amount of white blood cells called lymphocytes that attack and destroy joint tissue and other body parts. IL-1, another inflammatory cytokine, also contributes to the development of RA. IL-1 antagonists block the IL-1 receptor, which makes it less effective at stimulating the inflammatory process. This is why IL-1 blockers can be useful for treating RA, especially for people who have been on steroid medications for a long time and who are not getting the full benefit of their treatments. In November 2022, Eisai Co. Ltd. and Nippon Medac Co. Ltd. announced the launch of the anti-rheumatic agent “Metoject” Subcutaneous Injection 15 mg syring 0.30 mL, 12.5mg syring 0.25mL, 10mg syring 0.20mL, and 7.5mg syringe 0.15mL, in Japan for RA treatment.

Comments

Popular posts from this blog

With the use of High-Frequency alternating current, Radiofrequency Ablation Device convert Electromagnetic Energy into Heat Energy

The Isocyanates Market to Witness Robust Growth in North America and Asia Pacific

Air Purifier works as a Sanitizer in the air which helps in reducing pollutants, allergens, and toxins